Progyny (PGNY) moved back into focus after its latest earnings release combined a revenue beat with softer EBITDA and full year revenue guidance, a mix that coincided with a sharp share price pullback.
Progyny’s recent guidance reset came after a period where momentum had been slowly building. The company reported a 1-year total shareholder return of 16.88% and a 5.21% year to date share price return. However, its 3-year total shareholder return declined 22.52% and its 5-year total shareholder return declined 55.66%, reminding investors that sentiment around the stock has swung sharply over longer horizons as expectations for growth and risk have shifted.
Capitalize on the volatility around Progyny by scanning a curated 18 high quality undiscovered gems that share solid fundamentals yet remain under the radar.After Progyny’s guidance cut and the share price drop, investors are weighing whether the recent reset leaves more downside risk or a cleaner entry point. How far does the current valuation stretch that trade off?
Most Popular Narrative: 19.9% Undervalued
Progyny’s most followed valuation story tags fair value at $33.82 versus a last close of $27.08, framing the recent pullback as a sizeable discount to that narrative.
Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross-sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.
Read the complete narrative. Read the complete narrative.
Want to see what has to happen for Progyny to reach that fair value mark? The narrative leans on steady revenue expansion, rising profitability, and a richer earnings multiple that all need to line up.
Result: Fair Value of $33.82 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, if employers tighten benefit budgets or rival fertility offerings gain traction, Progyny’s revenue visibility and pricing power could look more fragile than this narrative assumes.
Find out about the key risks to this Progyny narrative.
Next Steps
Does the mixed mood around Progyny match your own view of the risk and reward trade off here, or does it feel a step too cautious given the data on hand? Take a moment to review the full picture yourself, then pressure test those green flags by digging into the 4 key rewards.
Looking for more Progyny sized ideas?
If Progyny has sharpened your focus, do not stop here. Broader research now can help you spot opportunities before the crowd catches on.
- Target potential mispricings and filter for companies that combine quality with compressed valuations through the 33 high quality undervalued stocks.
- Strengthen your defense by checking out the 11 resilient stocks with low risk scores that screens for businesses with more resilient risk profiles.
- Hunt for off-the-radar opportunities by tapping into a curated 18 high quality undiscovered gems with strong fundamentals that many investors still overlook.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com